Is HCG a bad choice for post-cycle therapy? Here's what the data says

What did @averyfisk_ actually say?

The creator argued that using HCG as a standalone post-cycle therapy is "a big mistake" because it only signals the testes directly and does not restart the hypothalamic-pituitary axis. They then recommended substituting HCG with enclomiphene, clomiphene, or Nolvadex (tamoxifen), and briefly mentioned blast-and-cruise as an alternative to coming off entirely.

To summarize the core claim: HCG makes the testes produce testosterone again without re-engaging the brain's signaling pathway, so stopping HCG leaves you back at square one. The creator also mispronounced or confused drug names throughout, calling clomiphene "Chlamophine" and HCG "HGG" multiple times. That matters, because if you're advising people on pharmaceutical compounds, getting the names right is the minimum bar.

Does the science back this up?

Partially, yes. The mechanistic point about HCG is largely correct. HCG is an LH analog that acts directly on the Leydig cells in the testes. It does not stimulate the pituitary to release FSH or LH, and it does not restore the feedback sensitivity of the hypothalamic-pituitary-gonadal (HPG) axis that anabolic steroid suppression disrupts.

Coviello et al. (2004, Journal of Clinical Endocrinology and Metabolism) showed that HCG administration during testosterone suppression maintained intratesticular testosterone but did not restore normal pituitary function. Boregowda et al. (2019, Clinical Endocrinology) similarly noted that exogenous LH-analog stimulation bypasses the hypothalamus entirely. So the creator's instinct is grounded in real endocrinology. Where the evidence gets more complicated is in how effective SERMs like clomiphene actually are at fully restoring the HPG axis after a prolonged suppression cycle. Recovery is not guaranteed with any approach.

What did they get wrong (or right)?

They got the core mechanism right but oversimplified the fix. Saying that clomiphene or tamoxifen will simply "signal the HPTA in your brain" and restart everything glosses over a more complicated reality. Kreher and Schwartz (2012, Sports Health) and several fertility medicine reviews note that SERM-based HPG axis recovery is inconsistent, particularly after long or high-dose steroid cycles. The pituitary can remain blunted even with SERM stimulation.

They also recommended blast-and-cruise as a straightforward "option," which deserves pushback. Blast-and-cruise means never coming off exogenous testosterone, which carries documented cardiovascular risks. Baggish et al. (2017, Circulation) found structural and functional cardiac abnormalities in long-term AAS users compared to non-users. Framing permanent testosterone suppression as a casual alternative to PCT is a significant omission, not a neutral choice. The creator should have flagged that.

• Right: HCG alone does not restore HPG axis feedback.
• Right: SERMs work at the hypothalamic-pituitary level.
• Wrong: SERMs are not a guaranteed or simple fix.
• Wrong: Blast-and-cruise was presented without any risk context.

What should you actually know?

HCG does have a legitimate role in PCT protocols, but typically as a preparatory step before SERM use, not as a standalone agent. Some endocrinologists use HCG in the weeks immediately after cycle cessation to maintain testicular size and responsiveness, then transition to a SERM to re-engage the pituitary. This combined approach has more clinical support than either intervention alone, as reviewed by Rahnema et al. (2014, Fertility and Sterility).

Enclomiphene, the trans-isomer of clomiphene, has a cleaner side-effect profile than standard clomiphene and has shown promise in hypogonadism trials (Kim et al., 2013, BJU International), but it remains off-label for PCT use and access varies by country. None of these compounds should be self-administered without medical oversight. Testosterone suppression from anabolic steroid use is a medical condition, and recovery attempts carry real risks including prolonged hypogonadism, mood disruption, and infertility that can require specialist care.

Bottom line

The creator identified a real pharmacological limitation of HCG-only PCT. That part is defensible. But the confident, simple framing, the mispronounced drug names, the lack of any dosing or duration caveats, and especially the casual endorsement of blast-and-cruise without risk disclosure make this video more likely to mislead than to inform a first-time cycle user. Credit where it's due on the mechanism. But the gaps here are real.